홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

S-(-)-카르비도파

Carbidopa

HCID 34359
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
28860-95-9
표준 SMILES
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
InChIKey
TZFNLOMSOLWIDK-JTQLQIEISA-N
분자식
C10H14N2O4
평균 분자량
226.23 g/mol
단동위원소 질량
226.09535693

개요

Carbidopa (anhydrous) is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an antiparkinson drug, a dopaminergic agent and an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor. It is a member of hydrazines, a monocarboxylic acid and a member of catechols.

이름 및 식별자

우선 이름
Carbidopa
IUPAC
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
현지명
S-(-)-카르비도파
영어명
S-(-)-Carbidopa
분자식
C10H14N2O4
분자량
226.23

이름 및 동의어

carbidopa28860-95-9LodosynCarbidopa anhydrousN-Aminomethyldopa(S)-(-)-carbidopaalpha-MethyldopahydrazineCarbidopumL-alpha-Methyldopahydrazine(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acidCarbidopa (anhydrous)(S)-carbidopa
이름 더 보기
S-(-)-카르비도파S(-)-CARBIDOPACarbidopa-d3mk486KINSONL-3-(3,4CARBIDOPA EDMFCarbidopa MonomerCARBIDOPAANHYDROUS
MK 486L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acidMK-486DTXSID4022735(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acidKR87B45RGH(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acidDTXCID502735

데이터베이스 식별자

CAS
28860-95-9、38821-49-7
PubChem CID
34359
DTXSID
DTXSID4022735
ChEMBL

물성

구조 계산 물성보충 중

XLogP
-2.2
극성 표면적
116 Ų
수소 결합 공여자 수
5
수소 결합 수용자 수
6
회전 가능 결합 수
4
무거운 원자 수
16
형식 전하
0
복잡도
261

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LogP-1.9
Human Drugs · 3건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling PointDecomposes
Melting Point · 2건

203-208 °C

203 - 205 °C

Physical DescriptionSolid
Dissociation Constants2.3
Collision Cross Section · 2건

142.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

143.39 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
203 · 203-205° (dec); mp 208°

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 6건

This chemical does not meet GHS hazard criteria for 2.7% (2 of 75) of reports.

Danger

H315 (82.7%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 75 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

유해성 정보

Regulatory InformationREACH registered substance: Carbidopa (EC: 249-271-9)
Hazard Classes and Categories · 2건

Skin Irrit. 2 (82.7%)

Muta. 2 (100%)

독성 정보

Adverse Effects · 1건

Because of the irreversible binding of AADC, carbidopa can decrease or deplete peripheral levels of serotonin, dopamine, norepinephrine, and epinephrine. Additionally, research has demonstrated that the irreversible binding of PLP causes nutritional deficiencies in vitamins B3 and B6. Specific carbidopa-induced dyskinesias, including “facial twitching and head bobbing,” have also been described.

Toxicity Summary · 1건

There is little data to suggest a possibility for or symptoms of carbidopa toxicity. However, reported data indicate that carbidopa/levodopa intestinal gel infusion can cause significant damage to small nerve fibers leading to pain and sensory discomfort.

Drug Induced Liver Injury · 6건

화학 및 산업

약리 정보

Protein BindingIt is widely accepted that the protein binding of carbidopa is 76%. However, more studies are required or the presentation of the source of this information.
Pharmacodynamics · 1건

When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.

Mechanism of Action · 1건

Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.

Biological Half-LifeThe reported half-life of carbidopa is of approximately 107 minutes.

관련 반응

6건
반응 기록 만들기
HRID 452338 반응식
HRID 452338생성물로
HRID 452339 반응식
HRID 452339반응물로
HRID 2212438 반응식
HRID 2212438반응물로
HRID 2212446 반응식
HRID 2212446반응물로
HRID 2212452 반응식
HRID 2212452반응물로
HRID 2242762 반응식
HRID 2242762반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
CHEMBL1200748、CHEMBL1201236
ChEBI
CHEBI:39585
UNII
KR87B45RGH
EC Number
249-271-9、657-445-4
Nikkaji
J17.160C
끓는 점
367.84 °C · 367.84°C (rough estimate)
밀도
1.2616 · 1.2616 (rough estimate)
굴절률
1.5 · 1.5000 (estimate)
저장 조건
-20 °C · -20°C
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
산도 계수 (pKa)
3.4 · 3.40±0.14(Predicted)
물리적 상태
가루
색상
흰색에서 황백색까지
안정성
솔루션이 불안정함
InChI
InChI=1/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/s3
InChIKey
TZFNLOMSOLWIDK-JQHDBZEONA-N
SMILES
[C@@](C)(NN)(C(=O)O)CC1C=CC(O)=C(O)C=1 |&1:0,r|

화학적 성질

White Solid

Drug Induced Liver Injury Rank (DILIrank 2.0)

Carbidopa

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6건

Carbidopa

1.6

6.9

Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 70 mg/day, Lowest Therapeutic Dose (LTD): 0.9 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

2-Jul-20

안전 데이터

wgk
3
rtecs
MW5298000
스토리지 클래스
11 - Combustible Solids
Metabolism/Metabolites · 1건

The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).

FDA Pharmacological Classification · 5건

MNX7R8C5VO

CARBIDOPA

Established Pharmacologic Class [EPC] - Aromatic Amino Acid Decarboxylation Inhibitor

Mechanisms of Action [MoA] - DOPA Decarboxylase Inhibitors

Carbidopa is an Aromatic Amino Acid Decarboxylation Inhibitor. The mechanism of action of carbidopa is as a DOPA Decarboxylase Inhibitor.

MeSH Pharmacological Classification · 3건

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism.

Absorption, Distribution and Excretion · 4건

When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.

In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.

The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.

The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.

용도 및 제조

UsesUse (kg; approx.) in Germany (2009): >5000
Use ClassificationPharmaceuticals

응용 분야

용도in combinaison with levodopa as antiparkinsonian;inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC)

일반 설명Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

상·하류 제품 정보

상류 원료

4-VinylphenolSodium bisulfite water solution다이에틸아민중아황산나트륨4-Hydroxyphenylacetone모노부틸아민사이안화 나트륨바닐린니트로에탄사이안화 칼륨염산철분하이드라진, 모노수화물브롬화수소아세트산(빙초산)
추가 설명 · 1건

정의ChEBI: 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversi n of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.